Results 31 to 40 of about 10,610 (205)

A correlative model to predict in vivo AUC for nanosystem drug delivery with release rate-limited absorption [PDF]

open access: yes, 2012
Purpose. Drug release from nanosystems at the sites of either absorption or effect biophase is a major determinant of its biological action. Thus, in vitro drug release is of paramount importance in gaining insight for the systems performance in vivo ...
Adibkia, Khosro   +6 more
core   +3 more sources

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience [PDF]

open access: yes, 2010
Background: Manifestation of acute edema in hereditary angioedema (HAE) is characterized by interindividual and intraindividual variability in symptom expression over time. Flexible therapy options are needed.
Aygören-Pürsün, Emel   +4 more
core   +2 more sources

Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C

open access: yesMedicine Science, 2016
Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus. Moderate and severe thrombocytopenia ( [Med-Science 2016; 5(1.000): 209-21]
Hosam Dawod, Sameh Abdel Monem
doaj   +1 more source

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

open access: yesGlobal & Regional Health Technology Assessment, 2022
Introduction: Hereditary angioedema (HAE) is a rare genetic disease that impairs quality of life and could be life-threatening. The aim of this study was to apply a multicriteria decision analysis to assess the value of three long-term prophylactic (LTP)
Néboa Zozaya   +9 more
doaj   +1 more source

Treatment of Hereditary Angioedema: items that need to be addressed in practice parameter [PDF]

open access: yes, 2010
Background Hereditary Angioedema (HAE) is a rare, autosomal dominant (AD) disorder caused by a C1 esterase inhibitor (C1-inh) deficiency or qualitative defect.
Callie Dagen, Timothy J Craig
core   +2 more sources

Idiopathic Thrombocytopenic Purpura Misdiagnosed as Hereditary Angioedema [PDF]

open access: yes, 2015
Hereditary angioedema is a rare, but potentially life-threatening genetic disorder that results from an autosomal dominant trait. It is characterized by acute, recurrent attacks of severe local edema, most commonly affecting the skin and mucosa. Swelling
Andersen, Michelle Fog, Bygum, Anette
core   +5 more sources

Thyroxin-bindendes Globulin (TBG) [PDF]

open access: yes, 1977
Zum Aufbau einer spezifischen radioimmunologischen Bestimmungsmethode von Thyroxin-bindendem Globulin (TBG) im Serum wurde eine reine TBG-Präparation hergestellt.
Horn, K.   +3 more
core   +1 more source

Hereditary angioedema may not be the only cause of abdominal pain in patients with hereditary angioedema!

open access: yesÇukurova Üniversitesi Tıp Fakültesi Dergisi, 2016
Abdominal pain is one of the basic clinical presentations of the hereditary angioedema and danazol is a common medicine which has been used for long years in patients with hereditary angioedema.
Ozgur Kartal   +7 more
doaj   +1 more source

Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia

open access: yesHematology, 2023
Objective This study aimed to evaluate the efficacy of azacitidine (AZA) combined with danazol (DNZ) and thalidomide (THD) maintenance therapy after intensive chemotherapy (IC) in patients with acute myeloid leukemia (AML).Methods we retrospectively ...
Fang Zheng   +5 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Home - About - Disclaimer - Privacy